Moberg Pharma delivered strongly in 2Q18, driven by an impressive performance in its US OTC business. Following the 2Q18 earnings report, we are substantially raising our forecast, leading to an increase in our valuation.

Read more and download the research update: https://www.redeye.se/company/moberg-pharma/580756/moberg-pharma-extraordinarily-strong-2q18

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/